Ask HopeStage to review this study with me
Leave your email and HopeStage can help you better understand this study.
Study reference: NCT04781140. HopeStage can help you review the study, but cannot decide medical eligibility.
RecruitingNCT04781140
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
This study is recruiting. It focuses on ADHD and currently lists participation information in the United States.
ADHDOtherFrom 48 Months to 69 Months
Key information made simple
This study is looking at evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD for people with Attention-Deficit/Hyperactivity Disorder. Participants receive 100mg SPN-812 or placebo and complete study visits and assessments. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
Your next step
The official record suggests in-person participation through a hospital, with sites including The Center for Clinical Trials, Inc in Saraland, Preferred Research Partners, Inc in Little Rock, and Advanced Research Center (ARC), Inc in Anaheim. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include major medical issues that could make participation unsuitable and active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means the approach is being followed in broader real-world use.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Main activity
- medication or study treatment
- Intervention
- Not available
- Time commitment
- multiple visits or assessments
- Study phase
- Not available
- Enrollment
- Not available
- Recruitment status
- Recruiting
- Source
- Official registry link
Key study information
- Official title
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- Condition
- Attention-Deficit/Hyperactivity Disorder
- Study status
- Recruiting
- Sponsor / lead affiliation
- Supernus Pharmaceuticals, Inc.
- Location / country
- United States
- Registry
- ClinicalTrials.gov
- External trial ID
- NCT04781140
Why this study may matter
This study may matter because it adds public evidence around adhd. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
For you
Taking part may help improve understanding of your condition.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Registry reference
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
- Official title
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- Source
- ClinicalTrials.gov
- Official registry link
- Open official registry
- External trial ID
- NCT04781140
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD?
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.
Who is behind this study, and what type of sponsor is it?
This study is sponsored by Supernus Pharmaceuticals, Inc., a pharmaceutical company. Supernus Pharmaceuticals is a pharmaceutical company focused on central nervous system conditions. The sponsor is based in the United States. Sponsor website: https://www.supernus.com. You can verify the sponsor and study responsibility in the official registry record.
What does participation involve, what phase is it, and what should I ask about safety?
This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Where can I verify the study details?
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me